Send a Tweet
Most Popular Choices
Share on Facebook 4 Share on Twitter Printer Friendly Page More Sharing
General News   

The Union to launch international trial of 9-month MDR-TB treatment regimen

By       (Page 1 of 2 pages)   No comments
Become a Premium Member Would you like to know how many people have read this article? Or how reputable the author is? Simply sign up for a Advocate premium membership and you'll automatically see this data on every article. Plus a lot more, too.
Author 43511
Follow Me on Twitter     Message Bobby Ramakant - CNS

World TB Day, 24 March 2010

In this year 2010, which has been declared as Year of the Lung, it is indeed a much-awaited welcome news that International Union Against Tuberculosis and Lung Disease (The Union) is to launch an International trial of 9-month MDR-TB treatment regimen. The need for accessible, effective multidrug-resistant tuberculosis treatment is urgent, as the incidence of MDR-TB continues to rise, and extensively drug-resistant TB (XDR-TB) has been reported in 57 countries. In response, the International Union Against Tuberculosis and Lung Disease (The Union) is launching a trial of a 9-month treatment regimen that has demonstrated cure rates exceeding 80% in a pilot programme.

While tuberculosis has been curable for more than 60 years, drug-resistant strains are far more difficult and costly to treat. Currently used treatment regimens can take up to two years to complete, placing a heavy burden on both patients and health systems.

The Union's evaluation of a standardised treatment regimen of anti-tuberculosis drugs for patients with multiple drug-resistant tuberculosis or STREAM will seek to determine whether a regimen developed and implemented by the Damien Foundation and the Institute of Tropical Medicine, and used with notable success in Bangladesh, can be used in different settings with comparable results.

"Obviously, this regimen represents a significant difference in time and resources for all involved", says Dr Nils E Billo, Executive Director of The Union. "But any treatment strategy must be carefully evaluated to ensure the most effective and feasible approaches are implemented, particularly in low-income settings where MDR-TB is most prevalent."

Next Page  1  |  2

(Note: You can view every article as one long page if you sign up as an Advocate Member, or higher).


Rate It | View Ratings

Bobby Ramakant - CNS Social Media Pages: Facebook page url on login Profile not filled in       Twitter page url on login Profile not filled in       Linkedin page url on login Profile not filled in       Instagram page url on login Profile not filled in

Bobby Ramakant is a World Health Organization (WHO) Director-General's WNTD Awardee for the year 2008, and writes extensively on health and development for Citizen News Service (CNS). Website:
Go To Commenting
The views expressed herein are the sole responsibility of the author and do not necessarily reflect those of this website or its editors.
Follow Me on Twitter     Writers Guidelines
Contact AuthorContact Author Contact EditorContact Editor Author PageView Authors' Articles
Support OpEdNews

OpEdNews depends upon can't survive without your help.

If you value this article and the work of OpEdNews, please either Donate or Purchase a premium membership.

If you've enjoyed this, sign up for our daily or weekly newsletter to get lots of great progressive content.
Daily Weekly     OpEdNews Newsletter
   (Opens new browser window)

Most Popular Articles by this Author:     (View All Most Popular Articles by this Author)

Tobacco smoking ruining lives: Lung cancer rates alarming

2010 is Year of the Lungs

Time for grown-ups to listen to young sane voices: Save fuel, save environment

The Union to launch international trial of 9-month MDR-TB treatment regimen

To View Comments or Join the Conversation: